28.01.2008 20:15:00
|
CORRECTING and REPLACING MicroIslet Announces the Appointments of Dr. Chris Marsh as Lead Transplant Advisor, and Dr. Ronald Goldblum as Lead Clinical Development Consultant
Please replace the release with the following corrected version due to
multiple revisions.
The corrected release reads:
MICROISLET ANNOUNCES THE APPOINTMENTS OF DR. CHRIS MARSH AS LEAD
TRANSPLANT ADVISOR, AND DR. RONALD GOLDBLUM AS LEAD CLINICAL DEVELOPMENT
CONSULTANT
MicroIslet Inc., (OTCBB: MIIS, http://www.microislet.com)
is a biotechnology company engaged in the development and
commercialization of transplantation therapies for diabetes. Today the
Company announced that Dr. Chris Marsh joined the Company’s
Scientific Advisory Board and was named MicroIslet’s
lead transplant consultant, and that Dr. Ron Goldblum has been retained
as the Company’s lead clinical development
consultant.
About Drs. Goldblum and Marsh
Ronald Goldblum, M.D.
Dr. Goldblum has over 19 years industry experience in clinical
development with his most recent position as Vice President in Clinical
Development at Elan Pharmaceuticals, Inc. where he had a major role in
the clinical development program for Tysabri. Dr. Goldblum is a
rheumatologist with clinical development expertise in autoimmune
disorders, immunology and inflammation, analgesia, and prevention of
graft rejection. He is the author of over 32 scientific publications and
also was Vice President at Neurobiological Technologies, Inc., Algos
Pharmaceuticals, and Ancile Pharmaceuticals. He has filed over 8 INDs
and has had a major role in multiple marketing application filings, both
in the US and Europe.
Christopher L. Marsh, M.D., F.A.C.S
Dr. Marsh is the chief of the Organ Transplantation Service in the
Division of General Surgery & Organ Transplantation and Co-Director of
the Center for Organ and Cell Transplantation at Scripps Green Hospital.
Previously, Dr. Marsh was associate professor of surgery and urology,
Director of the Kidney/ Pancreas Transplantation Program and associate
head of the Division of Organ Transplantation at the University of
Washington Medical Center in Seattle. Dr. Marsh attended medical school
and completed a urologic surgery residency at Loma Linda University in
Loma Linda, California, followed by a transplantation fellowship at the
Mayo Clinic in Rochester, Minnesota. Dr. Marsh is certified by the
American Board of Urology and is approved by the American Society of
Transplant Surgeons. He is a member of the American College of Surgeons,
American Society of Transplant Surgeons, American Society of Transplant
Physicians, International Pancreas and Islet Transplant Association, and
American and International Liver Transplant Societies and American
Urological Association. He has also served as president of the Urologic
Society for Transplantation and Vascular Surgery. He has written more
than 100 articles, chapters or abstracts and has held various positions
on national and regional transplantation and organ procurement
committees. He currently chairs the medical advisory committee to
LifeSharing, is a member of the UNOS liver an intestine committee and
pancreas committee and is the chair of the regional review board for
liver exceptions for Region V of UNOS.
Dr. Marsh’s active research activity includes
clinical trials using new immunosuppressive drug regimens in liver and
kidney transplants, pioneered steroid-free immunosuppression in organ
transplantation and helped initiate new protocols in islet
transplantation for the treatment of insulin requiring diabetes. He has
expertise in liver, kidney, pancreas and pancreatic islet
transplantation.
"Drs. Marsh and Goldblum bring a significant
breadth of understanding and expertise to our scientific and clinical
development plans. The entire team at MicroIslet is looking forward to
working closely with them to develop a successful transplantation
therapy for diabetic patients. We are very pleased to have them join our
efforts,” said Michael J. Andrews, MicroIslet’s
Chief Executive Officer.
About MicroIslet, Inc.
MicroIslet is a biotechnology company engaged in the research,
development, and commercialization of patented technologies in the field
of transplantation therapy for patients with insulin-dependent diabetes.
MicroIslet has licensed several technologies from Duke University for
isolation, culturing, storage, and microencapsulation of
insulin-producing islet cells from porcine sources. The Company believes
that these technologies, and other proprietary methods developed
in-house, are significant advances in the field of transplantation.
MicroIslet is planning human clinical trials in the U.S., and exploring
possible trials abroad. MicroIslet’s ultimate
goal is to offer cell transplantation therapies for diabetic patients
worldwide.
The Company’s lead product, MicroIslet-PTM,
consists of microencapsulated porcine islets for implantation into the
abdominal cavity using a minimally invasive procedure.
Microencapsulation involves surrounding islet cells with formulations of
a highly biocompatible, ultra-pure biopolymer, called alginate, or other
similar biocompatible polymers. The alginate coating allows insulin,
glucose, oxygen and other nutrients to diffuse freely, while blocking
antibodies and reducing the patient’s immune
response to the implanted islet cells. It is hoped that MicroIslet-PTM
will provide physiologic and self-regulating blood glucose control, thus
reducing the need for insulin injections or infusions and constant blood
glucose monitoring. The long term complications associated with type 1
diabetes, such as peripheral neuropathies, heart and kidney disease, and
skin disorders, may be mitigated by the tighter blood glucose control
that would result from such a product.
Additional information about MicroIslet can be found at http://www.microislet.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters set
forth in this press release are forward-looking statements within the
meaning of the "Safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially, including MicroIslet's
working capital deficit, which includes a substantial amount of
indebtedness which is matured and due on demand; MicroIslet’s
need to raise substantial additional funds in order to fund its new
strategy and continue as a going concern; the risks and uncertainties
inherent in medical treatment discovery; development and
commercialization; the risks and uncertainties associated with MicroIslet’s
early stage xenotransplantation technologies; the risks and
uncertainties of governmental approvals and regulation, including
foreign government approvals for clinical trials outside the United
States; dependence on a sole source supplier of animal parts and a sole
source manufacturer of encapsulated islets for pre-clinical and clinical
studies; the risks that MicroIslet’s
competitors will develop or market technologies or products that are
more effective or commercially attractive than MicroIslet’s
products; and other risks detailed from time to time in MicroIslet’s
most recent filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. MicroIslet
disclaims any intent or obligation to update these forward-looking
statements.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Microislet IncShsmehr Nachrichten
Keine Nachrichten verfügbar. |